EXHIBIT 235

SUMMARY OF FDA INSPECTIONAL HISTORY OF AMIDE PHARMACEUTICAL, INC.

MARCH 23, 1992

Amide signed a Consent Decree with the FDA.

EI DECEMBER 12, 1992

This December 12, 1992 to January 27, 1993 inspection was the first inspection conducted by the FDA after Amide entered into Consent Decree. An FD-483 was issued following conclusion of the inspection. A company response to the findings was submitted on January 27, 1993. In that response, Amide stated that it had investigated the problem areas, revised procedures, documented processes, and updated protocols accordingly. The District Office concluded that a re-inspection should be conducted to ascertain if Amide's commitments were being adhered to before the firm would be permitted to resume shipping their products.

EI MARCH 9, 1993

This re-inspection from March 9 to 17, 1993 resulted in a FD-483 being issued following the conclusion of the inspection. All the issues were addressed and as a result, we were permitted to freely manufacture and distribute all oral dosage form drugs that were dry blended. The one significant issue remaining from the inspection, drying oven qualification, was subsequently addressed and on May 7, 1993 the District gave us permission to proceed with those products using a wet granulation procedure.

EI MARCH 16, 1994

The inspection of March 16, 1994 to April 1994 was conducted to determine if the firm was operating in compliance with the terms of the Consent Decree and cGMP's. An FD-483 was issued at the conclusion of the inspection. Through a written response to the FD-483, Amide was able to demonstrate to the District office that, indeed, the process validation studies for these products had been completed prior to shipment of the products. No adverse comments to our FD-483 response were received from the District.

EI FEBRUARY 14, 1995

This pre-approval inspection for Digoxin Tablets Certification was conducted during eleven days between February 14 and March 16, 1995. Only one FD-483 observation was made at the conclusion of the inspection. A company response to the observation was submitted and the product was recommended for certification.



EI MAY 2, 1995

A pre-approval inspection of oral dosage form prescription drugs was conducted on this date. No FD-483 was issued. No adverse comments or observations were made concerning the products and the products were recommended for approval.

JUNE 8, 1995

FDA issued Batch certification to Amide, allowing Amide to initiate marketing of Digoxin Tablets (Generic to Lanoxin Tablets by [redacted].

JULY 20, 1995

FDA exempted Amide from the requirement for Digoxin Batch Certification. Based on the letter, Amide was not required to send each batch to FDA for batch certification. Amide could manufacture and market the product as needed.

SEPTEMBER 29, 1995

The FDA approved ANDA for [redacted]. This was our first ANDA after the signing of consent decree.

EI NOVEMBER 9, 1995

FDA conducted an inspection. No FD-483 was issued and the file was closed.

EI APRIL 23, 1996

The FDA conducted another pre-approval inspection on this date. An FD-483 was issued. Amide took the necessary actions, revised its SOPs, and submitted a timely response to the FD-483. FDA recommended approval of the product.

JULY 12, 1996

Amide requested FDA for the removal of Consent Decree based on its previous inspections.

EI OCTOBER 25, 1996

This inspection was conducted as the result of our initial request that the requirements of the Consent Decree be terminated. A FD-483 was issued as a result of the inspection. Amide responded to the FD-483 and no adverse comments to our FD-483 response were received from the District. However the district felt that the consent decree should not be removed at this time.

EI JANUARY 10, 1997

This inspection was a pre-approval inspection for (oral dosage form prescription drugs). No FD-483 was issued.

EI JANUARY 22, 1997

The FDA conducted an inspection. No FD-483 was issued.

FEBRUARY 28, 1997

Amide received approval of its first AB rated ANDA fo[redacted]

MARCH 7, 1997
Amide received ANDA approval fo[redacted]

MAY 8, 1997
Amide received supplemental approval for its ANDA[redacted]

EI MAY 14, 1997

Another pre-approval inspection was held on this date. No FD-483 was issued. The EIR stated that the inspection covered a review of documentation pertaining to several prescription drug products. The review included but was not limited to product development reports, validation protocols, master batch records, executed batch records and associated raw data. The EIR states: "The inspection did not reveal any cGMP deficiencies".

MAY 30, 1997

Amide received ANDA approval fo[redacted]

JUNE 18, 1997

Amide received ANDA approval fo[redacted]. This is the first ANDA in FDA's history to be approved in one cycle (approximately 6 months).

JUNE 19, 1997

Amide received ANDA approval fo[redacted] This ANDA was also approved in one cycled (approximately 6 months).

JULY 25, 1997

Amide requested that the FDA remove the Consent Decree based on its previous inspections.

EI NOVEMBER 4, 1997

This was a cGMP inspection conducted as a follow-up to Amide's second request of July 25, 1997 to be removed from the terms of the Consent Decree. An FD-483 was issued at the completion of the inspection. A company response to the FD-483 was submitted and reviewed by the District office. After much discussion between the District office and Amide representatives, Amide's response was deemed to be adequate and it was decided that a follow-up inspection would be made to confirm Amide's actions.

DECEMBER 10, 1997

Amide received approval for its ANDA for[redacted]

EI JANUARY 30, 1998

At the conclusion of this inspection for sample collection, the FDA did not issue an FD-483.

EI APRIL 2, 1998

This inspection was a pre-approval inspection covering three ANDA products. An FD-483 was issued containing only one observation. After submitting written response to the District office, Amide obtained approvable status for all the products.

EI OCTOBER 28, 1998

This FDA inspection was a pre-approval inspection (for oral dosage form prescription drugs). No FD-483 was issued.

EI NOVEMBER 16, 1998

The FDA conducted a routine inspection and no FD-483 was issued.

EI DECEMBER 2, 1998

The latest cGMP inspection was concluded on January 8, 1999. An FD-483 was issued. Amide revised its procedures, retrained employees, and made a timely response to the FD-483 without adverse comment on the part of the District office. At the conclusion of this inspection, FDA recommended removal of Consent Decree. Amide followed through on the FDA's recommendation, but unfortunately upon further review by FDA, they decided not to remove the Consent Decree.

DECEMBER 29, 1998

Amide received approval for its ANDA for [redacted]

DECEMBER 30, 1998

Amide received ANDA approval for [redacted]

EI MARCH 2, 1999

The FDA conducted a routine inspection and no FD-483 was issued.

MARCH 15, 1999

Amide received ANDA approval for [redacted]

MAY 26, 1999

Amide received ANDA approval for [redacted]

MAY 28, 1999

Amide received ANDA approval for [redacted]

EI SEPTEMBER 17, 1999

This was a follow up inspection to review the flood damage caused by Tropical Storm Floyd. No FD-483 was issued at the conclusion of the inspection.

OCTOBER 22, 1999

Amide received ANDA approval for [redacted]

EI NOVEMBER 8, 1999

This inspection was a pre-approval inspection for our pending ANDA products. An FD-483 was issued at the conclusion of the inspection. After submitting its written response to the District office, Amide obtained approvable status for all the products.

DECEMBER 23, 1999

Amide received ANDA approval for Digoxin Tablets, USP 0.125 mg and 0.25 mg.

FEBRUARY 28, 2000

Amide received ANDA approval for [redacted]

MARCH 14, 2000

Amide received ANDA approval for [redacted]

MAY 23, 2000

This inspection was a pre-approval inspection covering three ANDA products. A FD-483 was issued at the conclusion of the inspection. After submitting our written response to the District office, obtained approvable status for all the products

JULY 26, 2000

Amide received ANDA approval fo [redacted]

DECEMBER 1, 2000

Amide received ANDA approval fo [redacted]

EI APRIL, 2001

This inspection was a pre-approval inspection. No FD-483 was issued at the conclusion of the inspection.

JULY 11, 2001

Amide received ANDA approval for [redacted]

EI NOVEMBER 29, 2001

This inspection was a general cGMP inspection and a pre-approval inspection. A one point FD-483 was issued at the conclusion of the inspection. After submitting our written response to the District office, obtained approvable status for all the products.

MAY 9, 2002

Amide received ANDA approval for [redacted]

JUNE 10, 2002

Amide was formally released from the terms of the consent decree.

AUGUST 2, 2002

Amide received ANDA approval for [redacted]

EI NOVEMBER 13, 2002

This inspection was a follow-up to the fire in room 123 on 8/19/2002. . No FD-483 was issued at the conclusion of the inspection.

NOVEMBER 14, 2002

Amide received ANDA approval for [redacted]

JANUARY 14, 2003

Amide received ANDA approval for [redacted]

JANUARY 14, 2003

Amide received ANDA approval for [redacted]

JANUARY 22, 2003

Amide received ANDA approval for [redacted]

EI MARCH, 2003

This inspection was a general cGMP inspection and a pre-approval inspection. A two point FD-483 was issued at the conclusion of the inspection. After submitting our written response to the District office, obtained approvable status for all the products.

EI APRIL , 2003

This inspection was a general cGMP inspection for the approval of our new facility at 4 Taft Roadand a pre-approval inspection. A one point FD-483 was issued at the conclusion of the inspection. After submitting our written response to the District office, obtained approvable status for all the products.

JUNE 25, 2003

Amide received ANDA approval for [redacted]

AUGUST 20, 2003

Amide received ANDA approval fo[redacted]

EI AUGUST 21, 2003

This inspection was a pre-approval inspection. A two point FD-483 was issued at the conclusion of the inspection. After submitting our written response to the District office, ANDA was deemed approvable by the District Office. Amide is awaiting approval by the center.

OCTOBER 20, 2003

Amide received ANDA approval for [redacted]

EI NOVEMBER 26, 2003

This inspection was for collecting forensic samples for Amide product. No FD-483 was issued at the conclusion of the inspection.

EI FEBRUARY 5, 2004

This inspection was for collecting forensic samples for Amide product. No FD-483 was issued at the conclusion of the inspection.

FEBRUARY 6, 2004

Amide received ANDA approval for [redacted]

MARCH 31, 2004

Amide received ANDA approval for [redacted]

REMARKS:

Amide has responded in a timely and aggressive manner to each of the concerns expressed in the FDA's FD-483 observations. In fact, Amide's written responses documenting actions taken in response to the FD-483 observations in most cases have been accepted by the District without further comment or instruction. Furthermore, in the past nine years, the District has not suggested the recall of any of Amide's products, nor taken any action against Amide beyond issuing the FD-483's.